Immunovaccine has completed crucial scale-up and manufacturing method development for the DepoVax™ platform which is applicable to all of the company’s subsequent human health vaccines. The scale-up methods have been transferred to a reputable contract GMP development and manufacturing facility. This site has an establishment license from Health Canada, which allows it to manufacture sterile products for clinical and commercial purposes. Dedicated, company-owned equipment has been purchased and installed at the site.
Immunovaccine has manufactured commercial scale vaccine batches, including the most recent 50 litres (200,000 doses) of a Hepatitis B vaccine. This accomplishment is particularly important because historically, large-scale production of liposomes has been a significant challenge. Immunovaccine has confirmed both the stability and that the biological activity of the batch is equivalent to laboratory batches.